155 13F filers hold it · −14 against the quarter before · shares held +19.6%
Holdings of 06/30
Stocks
All insider trades in Fulcrum Therapeutics
All planned sales of Fulcrum Therapeutics
Fulcrum Therapeutics FULC
Health care sectorNasdaq
What to see in Fulcrum Therapeutics now
Company
- Exchange
- Nasdaq
- Sector
- Health care
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, Massachusetts
- Fiscal year end
- 12/31
- Next earnings
- 07/01, estimated
- $54.4K of planned sales filed in 30 days · under 0.1% of the units outstandingFiled 09/02
Insider trades
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
Alan EzekowitzDirector | Open-market sale | 06/26 | 06/30 | 18,000 sh | $3.65 | $65,700 | −62.2% |
Robert J. GouldDirector | Open-market sale | 02/02 | 02/04 | 15,000 sh | $10.72 | $160,800 | −3.2% |
Robert J. GouldDirector | Open-market saleAmendment | 01/02 | 02/04 | 15,000 sh | $10.87 | $163,050 | −3.1% |
Robert J. GouldDirector | Open-market sale | 01/02 | 01/06 | 15,000 sh | $11.87 | $178,050 | −3.1% |
Curtis Gale OltmansChief Legal Officer | Open-market sale | 25/12/15 | 25/12/17 | 3,452 sh | $12.92 | $44,599.84 | −25.2% |
Planned sales
Greg Tourangeauformer officer | Fulcrum TherapeuticsFULC | 14,062 sh | $54,419.94 | 09/02 | Filed 09/02 |
Alan EzekowitzDirector | Fulcrum TherapeuticsFULC10b5-1 plan | 18,000 sh | $64,980 | 06/26 | Filed 06/26 |
Curtis Gale OltmansOfficer | Fulcrum TherapeuticsFULC10b5-1 plan | 3,452 sh | $44,876 | 25/12/15 | Filed 25/12/15 |
RA Capital Healthcare Fund10% Stockholder | Fulcrum TherapeuticsFULC | 4,175,139 sh | $54,235,055.61 | 25/12/08 | Filed 25/12/08 |
Robert J. GouldDirector | Fulcrum TherapeuticsFULC10b5-1 plan | 45,000 sh | $437,850 | 25/11/19 | Filed 25/11/19 |